Creaspac (CPAC-SPAC.ST) Stock Analysis & AI Equity Report

Shell Companies SEK Explore free reports

Creaspac (CPAC-SPAC.ST) overview

Creaspac (CPAC-SPAC.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Creaspac reported revenue of SEK 0m and operating profit of SEK -6.0m; the year-end share price was 97.40 SEK and market capitalisation was SEK 2,435m. Creaspac is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Creaspac's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 2,533mFY 2023
Share price97.40 SEKFY 2023 year end
RevenueSEK 0mFY 2023
Operating profitSEK -6.0mFY 2023
Net earningsSEK 61.2mFY 2023
Market capitalisationSEK 2,435mFY 2023 year end

Figures updated on 2025-09-05. Data will be refreshed during report generation.

About Creaspac

Creaspac AB (publ) was a Swedish special purpose acquisition company established by Creades in 2021 to raise capital through a listing and acquire an unlisted business within a set timeframe. It listed on Nasdaq Stockholm in June 2021, was delisted in July 2024, and subsequently entered voluntary liquidation.

Generate the Creaspac report

Creaspac is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Creaspac and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.